环状RNA参与卵巢癌铂耐药相关机制的研究进展
Research progress on the mechanism of circular RNA involved in platinum resistance in ovarian cancer
刘彬馨 1范雅丹 1吕春燕 1梅子曼 1邓青春1
作者信息
- 1. 海南医学院第二附属医院妇科,海南 海口 570100
- 折叠
摘要
卵巢癌因早期诊断困难、确诊时多为晚期以及高复发率,成为致死率最高的妇科肿瘤.卵巢癌不良预后的重要原因是对铂类抗肿瘤化疗药物的耐药.环状RNA(circRNA)因其特殊的结构在细胞中较mRNA更稳定,参与调控多种肿瘤的发生、发展及化疗耐药.circRNA可作为miRNA的竞争性内源性RNA(ceRNA)与蛋白结合,可通过调控巨噬细胞表型极化,和作为外泌体circRNA参与调控卵巢癌铂耐药的敏感性.circRNA有望成为新的铂耐药标志物及耐药治疗新靶点.为了进一步探讨circRNA与卵巢癌铂耐药的关系,本文对近年来有关circRNA与卵巢癌铂耐药相关研究的文献进行总结.
Abstract
Ovarian cancer has become the most lethal gynecological tumor due to the difficulty in early diagnosis,the late stage when diagnosed and the high recurrence rate.Resistance to platinum-based anti-tumor chemotherapy drugs is an important reason for the poor prognosis of ovarian cancer.circular RNA(circRNA)is more stable than mRNA in cells due to its special structure,and it is involved in the regulation of the occurrence,development and chemotherapy resistance of a variety of tumors.circRNA can be used as a competing endogenous RNA(ceRNA)of miRNA to bind to proteins,and regulates the phenotypic polarization of macrophages,it can also be used as an exosomal circRNA to regulate the sensitivity of platinum resistance in ovarian cancer.circRNA is expected to be a new marker of platinum resistance and a new target for the treatment of platinum resistance.In order to further explore the relationship between circRNA and platinum resistance in ovarian cancer,this article summarizes the recent literature related to circRNA and platinum resistance in ovarian cancer.
关键词
环状RNA/卵巢癌/铂耐药/机制/综述Key words
circular RNA/ovarian cancer/platinum resistance/mechanism/review引用本文复制引用
基金项目
海南省自然科学基金高层次人才项目(2021)(821RC712)
海南省重点研发计划(2022)(ZDYF2022SHFZ068)
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据